FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Optio

FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment Link To Press Release